BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2013

View Archived Issues

Volasertib inferior to pemetrexed in phase II trial for NSCLC

Read More

Farletuzumab misses phase II endpoint for NSCLC

Read More

Small-molecule antagonists identified for the treatment of light-sensitive migraine

Read More

Isis Pharmaceuticals begins phase II trial of ISIS-GCCRRx in combination with metformin

Read More

RINT1 gene mutations linked to early-onset breast cancer

Read More

Phase I data for the GS-4774 vaccine confirm tolerability and immunogenicity

Read More

Otsuka and Lundbeck partner for nalmefene in Japan

Read More

CRT Pioneer Fund and Chroma form collaboration to develop anticancer drugs targeting macrophages

Read More

Mochida Pharmaceutical synthesizes novel FFA1 agonists

Read More

Fidelity Biosciences and ReGenX Biosciences launch new company

Read More

Achillion details development of hepatitis C virus candidate ACH-3422

Read More

New gamma-carbolines designed at IntraCellular Therapies

Read More

Chinese and U.S. team patents novel HD6 inhibitors

Read More

arGEN-X and de Duve Institute/UCL sign collaboration to develop immunomodulation therapy for cancer

Read More

Testing supports development of Pluristem's PLX cells for pre-eclampsia

Read More

Pfizer provides overview of third quarter 2013

Read More

Dainippon Sumitomo Pharma provides overview of second quarter of fiscal 2013

Read More

BioLineRx receives approval to begin trial of BL-7010 in celiac disease

Read More

Ampio Pharmaceuticals reports data from extension of SPRING study

Read More

Allegro Ophthalmics begins phase II study of ALG-1001 for vitreomacular traction

Read More

New IL-17 production inhibitors disclosed by Mitsubishi Tanabe Pharma

Read More

Almirall submits MAA in Europe for fixed-dose aclidinium and formoterol

Read More

LC-540449 demonstrates efficacy in a preclinical model of non-alcoholic steatohepatitis

Read More

Genkyotex begins multinational phase II study of NOX inhibitor

Read More

Actelion launches Opsumit for treatment of PAH in the U.S.

Read More

Thomson Reuters and NuMedii collaborate on drug repurposing initiative

Read More

AB Science to advance masitinib to phase III development for treatment of ALS

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing